Compare Merck & Co., Inc. (MRK) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Quantum Computing Inc — how do they compare? Merck & Co., Inc. trades at $133.37 (market cap $321.77B), while Quantum Computing Inc trades at $8.95 (market cap $2.03B). The key difference: Merck & Co., Inc. is far larger — about 158.5× Quantum Computing Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| MRK | QUBT | |
|---|---|---|
Market Cap | $321.77B | $2.03B |
Sector | Health | Technology |
52-Week High | $131.84 | $24.62 |
52-Week Low | $77.60 | $6.31 |
Enterprise Value | $368.53B | $1.09B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Quantum Computing Inc. (QUBT) trades at $8.91, down 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of $5.6 million, a significant increase year-over-year, though it posted a net loss. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, suggesting substantial upside potential from current levels.
QUBT presents high-risk, high-reward potential as it transitions to commercial scaling, with strong revenue growth offset by persistent losses and negative margins. Key risks include execution challenges in manufacturing expansion and intense competition in the quantum computing sector. The stock's valuation remains steep with a P/S ratio of 189.05, requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
